04/09/2025
Our team has a new clinical trial for individuals 1-45 years old to look at the safety, tolerability, and effectiveness of a new investigational drug called RZ358, also known as the sunRIZE study with Rezolute Pharma! RZ358 is being studied as part of this clinical trial and is not yet FDA-approved. It is a specialized protein (called a monoclonal antibody) meant to decrease the effect insulin has on lowering blood sugar and, therefore, improve blood sugar levels in patients with hyperinsulinism. Participation will last for up to 33 weeks or up to 3 years overall if you also join the open-label extension phase of the study. This includes a 5-week Screening Period, a Treatment Period that lasts 24 weeks, an 8-week Follow-up Period, and a 2-year Extension Period where you can continue to receive the study drug if you and the study doctor agree it is beneficial for you. You do not need to participate in the 2-year extension part of the study to take part in the treatment and monitoring period. Travel and compensation are provided! For more information, please contact us at HIResearch@chop.edu.
